This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna May Supply 40M Coronavirus Vaccine Doses to Japan
by Zacks Equity Research
Moderna (MRNA) is negotiating a deal with Japanese authorities for supply of its coronavirus vaccine in Japan, following a potential approval.
Novartis Announces Positive Data on PNH & Cholesterol Drugs
by Zacks Equity Research
Novartis (NVS) announces new positive data on its PNH drug, LNP023, and an investigational cholesterol-lowering treatment, inclisiran.
Novartis' (NVS) Leukemia Drug Meets Goal in Late-Stage Study
by Zacks Equity Research
Novartis' (NVS) chronic myeloid leukemia candidate meets primary endpoint in a phase III study.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $152.30, marking a +0.16% move from the previous day.
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
by Sweta Killa
While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.
Teva Stock Down on Charges of Illegal Generic Price Fixing
by Zacks Equity Research
Teva (TEVA) has been indicted on charges of conspiring with other generic drugmakers to raise prices for generic drugs.
AstraZeneca Coronavirus Vaccine May Get FDA's Emergency Tag
by Zacks Equity Research
AstraZeneca's (AZN)/Oxford's AZD1222 is in phase II/III study in the UK, Brazil and South Africa with a late-stage study due to start soon in the United States with 30,000 participants.
Top Stock Reports for JNJ, Procter & Gamble & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Procter & Gamble (PG) and Thermo Fisher (TMO).
FDA Grants Emergency Use to Plasma Therapy to Treat Coronavirus
by Kinjel Shah
Convalescent plasma contains antibodies that can fight off the disease faster and prevents COVID-19 patients from getting severely ill.
Stock Market News for Aug 24, 2020
by Zacks Equity Research
Rally in large-cap technology-related firms helped the Nasdaq hit another record high this year on Friday.
Novartis' Immunotherapy Fails in Late-Stage Skin Cancer Study
by Zacks Equity Research
Novartis' (NVS) phase III study evaluating the investigational immunotherapy, spartalizumab, in combination with the targeted therapies, Tafinlar and Mekinist, fails to achieve goals.
Amgen's New Kyprolis Combo Gets FDA Nod for Multiple Myeloma
by Zacks Equity Research
Amgen's (AMGN) Kyprolis gets FDA approval for label expansion as second to fourth-line treatment for relapsed/refractory multiple myeloma in combination with J&J's Darzalex and dexamethasone.
Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals
by Kinjel Shah
J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma
ETFs in Focus on Momenta Buyout Deal With JNJ
by Sweta Killa
A number of ETFs could be the best ways for investors to tap the opportunity arising from the Momenta buyout deal.
J&J to Buy Momenta for $6.5B to Boost Autoimmune Presence
by Zacks Equity Research
J&J (JNJ) offers to buy Momenta, which focuses on the development of novel drugs to treat rare, immune-mediated disorders.
Momenta Surges on Acquisition Deal With Johnson & Johnson
by Zacks Equity Research
Momenta (MNTA) soars on the announcement of being acquired by Johnson & Johnson for $6.5 billion.
Company News for Aug 20, 2020
by Zacks Equity Research
Companies In The News Are: MNTA, JNJ, TGT, REGN, GLPG, GILD.
S&P 500 Records a Fresh All-Time High
by Zacks Equity Research
S&P 500 Records a Fresh All-Time High.
Pre-Markets Mixed Following S&P 500's Fresh High, Strong Earnings
by Zacks Equity Research
Market participants enjoyed an astonishing 54.7% rally of the broad-market S&P 500 Index since its crash on Mar 23.
Opioid Crisis Deepens as Teva, Allergan Face Fraud Charges
by Kinjel Shah
The DFS charges claim that Teva (TEVA) and Allergan (AGN) used fraudulent marketing and promotional campaigns to promote their opioid products
AstraZeneca (AZN) to Supply Coronavirus Vaccine in Europe
by Zacks Equity Research
AstraZeneca (AZN) closes a deal with the European Commission for supplying at least 400 million doses of its COVID-19 vaccine, AZD1222, if approved.
Why Is Johnson & Johnson (JNJ) Down 0.7% Since Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mesoblast Gets Favorable Votes From FDA Committee for Ryoncil
by Zacks Equity Research
Mesoblast (MESO) gets ODAC's vote in the ratio of 9:1 for GVHD drug.
US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch
by Ritujay Ghosh
The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.
Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes
by Kinjel Shah
The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.